Develops treatments for inflammatory and metabolic diseases, focusing on novel therapies.
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced therapeutics aimed at addressing critical medical needs across various disease areas. Headquartered in Cupertino, California, the company focuses on pioneering treatments for central nervous system disorders, respiratory illnesses, cardiovascular conditions, metabolic disorders, and inflammatory diseases. At the forefront of its pipeline is RP5063, currently undergoing Phase III clinical trials for schizophrenia treatment. RP5063 has also advanced through Phase I trials targeting bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder (ADHD), and other psychiatric and neurodegenerative conditions, including Parkinson's disease psychosis and pulmonary arterial hypertension.
In addition to RP5063, Reviva Pharmaceuticals is actively developing RP1208, a promising candidate in pre-clinical stages for the treatment of depression and obesity. The company leverages innovative research and development strategies to explore novel therapeutic avenues and enhance patient outcomes through its robust pipeline of potential therapies.
Founded on a commitment to scientific excellence and patient-centric innovation, Reviva Pharmaceuticals collaborates with leading researchers and healthcare professionals to advance its portfolio of transformative treatments. With a strong emphasis on addressing unmet medical needs, the company continues to drive forward with the goal of bringing new hope and effective therapies to patients worldwide.